natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the active indicator substance is present with a binding agent or a lubricant in a mixture. The method of claim 1, wherein the active indicator substance comprises at least one UV indicator substance selected from the group consisting of flavonic acid, 4,4′-distyryl-biphenyls, stilbenes, pyrazolines, coumarin, dihydroquinolines, naphthalene acid imides, benzoaxazole, benzioxazole compounds, riboflavin, quinine, chlorogenic acid, quinoline yellow, and derivatives thereof. 
Mineralna vuna kao proizvod u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što mineralna vuna kao proizvod sadrži najmanje jednu UV-aktivnu komponentu, koju se bira iz skupine koju čine: flavonska kiselina, 4,4′-distirilbifenili, stilbeni, pirazolini, kumarin, dihidrokinolini, imidi naftalenske kiseline, benzoksazol, spojevi benzoksazola, riboflavin, kinin, klorogenska kiselina, kinolinsko žutilo i njegovi derivati.
The method of claim 2 wherein: the slurry includes an acid other than the hop compound, and the acid is selected from the group consisting of phosphoric acid, sulfuric acid, hydrochloric acid, nitric acid, tartaric acid, lactic acid, tannic acid, acetic acid, oxalic acid, citric acid, and mixtures thereof. 
Postupak prema zahtjevu 2, naznačen time što: suspenzija sadrži drugu kiselinu od spoja hmelja, i kiselina je izabrana iz skupine koju čine fosforna kiselina, sumporna kiselina, klorovodična kiselina, nitratna kiselina, vinska kiselina, mliječna kiselina, taninska kiselina, octena kiselina, oksalna kiselina, limunska kiselina, i njihove smjese.
A pyrazolo pyridine derivative according to Formula (I), wherein G1, G2, G3, G4 and G5 are as defined in any one of the preceding claims, tautomers, geometrical isomers, optically active forms as enantiomers, diastereomers and racemate forms, as well as pharmaceutically acceptable salts thereof, for use in the prophylaxis or the treatment of a disease or condition selected from cardiovascular disorders, respiratory disorders, metabolism disorders, skin disorders, bone disorders, neuroinflammatory and/or neurodegenerative disorders, kidney diseases, reproduction disorders, diseases affecting the eye and/or the lens and/or conditions affecting the inner ear, inflammatory disorders, liver diseases, pain, cancers, allergic disorders, traumatisms, septic, hemorrhagic and anaphylactic shock, diseases or disorders of the gastrointestinal system and other diseases and/or disorders associated with Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). 
Derivat pirazolopiridina opće formule (1), naznačen time, što su Gi, G,, G3, G, i Gs kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva, njegovi tautomeri, geometrijski izomeri, optički aktivni oblici odnosno enantiomeri, dijastereoizomeri i racemski oblici, kao i njegove farmaceutski prihvatljive soli, za upotrebu u profilaksi 1li tretmanu bolesti ili stanja izabranih iz grupe koju čine kardiovaskularni poremećaji, respiratorni poremećaji, metabolički poremećaji, poremećaji kože, poremećaji u kostima, neuroinflamatorni i/ili neurodegenerativni poremećaji, bolesti bubrega, reproduktivni poremećaji, bolesti koje utječu na oko i/ili leću oka i/ili stanja koja utiču na unutrašnje uho, inflamatorni poremećaji, bolesti jetre, bol, rak, alergijski poremećaji, traumatizmi, septički, hemoragijski 1 anafilaktički šok, bolesti ili poremećaji gastrointestinalnog sistema, kao i druge bolesti 1 poremećaji koje prati izmijenjena aktivnost nikotinamid adenin dinukleotid fosfat oksidaze (NADPH oksidaze).
The compound of claim 1, wherein Y is -CH2 or deleted and Z is -CH2-. 
Spoj prema zahtjevu 1, naznačen time da Y je -CH> ili izbrisan i Z je -CH>-.
the glass plug positioned in the neck of the container and having a through passage, and a radially outer surface radially inward of the second radially inner surface of the second retainer, wherein the bonding material is disposed between the container and the glass valve retainer. 
114, 214, 414, 614) u unutarnjem prolazu grla spremnika, tako da se vezivni materijal stavlja između unutarnje površine grla spremnika i nastavka: i
The sustained release polymer and the optional plasticizer used in step (3) can be further combined with an antisticking agent, such as talc. 
Polimer za produljeno otpuštanje i izborni plastifikator upotrijebljen u koraku (3) može se daljnje kombinirati sa sredstvom protiv sljepljivanja, poput talka.
a DNA-targeting RNA comprising: a DNA-targeting segment comprising a nucleotide sequence that is complementary to a sequence in the target DNA, and 
segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna ciljanoj sekvenci u ciljanoj DNK; i
discharge of the emulsion of fluid components from the washing chamber (101) through the outlet (103) of the washing and separating container (1) and density gradient removal of the emulsion of fluid components. 
pražnjenja emulzije od tekućih komponenti iz komore (101) za ispiranje kroz odvod (103) spremnika (1) za ispiranje i odvajanje; -
This may include inserting “gaps” in either one or both sequences, to enhance the degree of alignment. 
To može uključivati unos "praznina" u jednom ili oba slijeda, kako bi se povećao stupanj poravnatosti.
u, v, R1, and R2 are as described for formula (7); and LG is a leaving group; with a compound of formula (4) 
LK gdje u, v, R',i R? su kako je opisano za formulu (7); i LG je odlazeća skupina; sa spojem formule (4) oo bA ', Å A ša o ia
The method according to claim 1, wherein a value of the active OFDM symbol duration field is one of 448 µs at 4k Fast Fourier Transformation, FFT, mode for 8 MHz bandwidth transmission system and 448 x (8/6) µs at 4k FFT mode for 6 MHz bandwidth transmission system. 
Postupak prema zahtjevu 1, gdje je vrijednost aktivnog OFDM polja trajanja simbola jedna od 448 us na 4k brzih Fourierovih transformacija (FFT), mod za prijenosni sustav od 8 MHz širine pojasa 1 448 x (8/6) us na 4k FFT mod za prijenosni sustav od 6 MHz širine pojasa.
sequentially positioning a number of the plurality of waterproof tubular panels on the bottom and/or on the side banks of the canal or water basin; 
uzastopno postavljanje niza vodonepropusnih ploča (14; 14A) na dnu (11) i / ili na bočnim stranama (12) kanala ili vodenog bazena (10);
The sulphate salt of claim 2, having formula III wherein 
Sulfatna sol iz patentnog zahtjeva 1, koja ima formulu III
providing a biphasic mixture comprising the compound of formula (XXIII), an organic boronic acid acceptor, a lower alkanol, a C5-8hydrocarbon solvent, and aqueous mineral acid; 
(i) osiguravanje dvofazne smjese koja sadrži spoj formule (XXIII), organski akceptor organoborne kiseline, niži alkanol, Cs.g ugljovodično otapalo i vodenu otopinu mineralne kiseline;
the antiinfective agents selected from antibiotics or antivirals. A process for preparing compounds of formula (Ia) wherein T is absent or (Ib) as defined in claim 1, which comprises: 
Postupak dobivanja spojeva formule (Ia), gdje T je odsutan ili (Ib) je kao što je definirano u patentnom zahtjevu 1, gdje se navedeni postupak sastoji u:
wherein R4 is as defined for a compound of the formula I in the presence of a base and a palladium(II) compound in the presence of an inert solvent; where the above starting compounds II and III may also be present with functional groups in protected form if necessary and/or in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible; any protecting groups in a protected derivative of a compound of the formula I are removed; and, if so desired, an obtainable compound of formula I is converted into another compound of formula I, a free compound of formula I is converted into a salt, an obtainable salt of a compound of formula I is converted into the free compound or another salt, and/or a mixture of isomeric compounds of formula I is separated into the individual isomers. 
(li) u kojoj su R,, R2, Ra, Rs, Rs1n isti kao što su određeni za spoj formule I, reagira s boronskom kiselinom formule III R4-B(OH), (1) gdje je Ry određen kao za spoj formule I, u prisutnosti baze, i sa spojem paladija(II) u prisutnosti inertnog otapala; pri čemu gore navedeni početni spojevi II i III, mogu također biti prisutni s funkcionalnim skupinama u zaštićenom obliku, ako je to potrebno, i/ili u obliku soli, pod uvjetom da je prisutna skupina koja tvori sol te da je moguća reakcija u obliku soli; odstranjuju se sve zaštitne skupine od zaštićenog derivata spoja formule; i, ako se želi, pretvara se dobiveni spoj formule I u drugi spoj formule I, a slobodni spoj formule I se pretvara u sol, zatim se dobivena sol spoja formule I pretvara u slobodan spoj ili u drugu sol, i/ili se odvaja mješavina izomernih spojeva formule I u individualne izomere.
The Triton-X45 reduces the surface tension of the composition and facilitates the formation of a very uniform coating on the surface of the produce, which is preferable for consistent performance. 
Triton-X45 smanjuje površinski napon kompozicije i olakšava formiranje vrlo ujednačene ovojnice na površini proizvoda, koja je poželjna za ujednačeni učinak.
In particular, the hydrophilic matrix corresponds to substances selected, for example, from cellulose derivatives, such as hydroxyalkylcelluloses, alkylcelluloses, carboxyalkylcelluloses and their salts or derivatives, polyvinyl alcohols, carboxyvinyl derivatives, polysaccharide derivatives of anionic or cationic nature, such as, for example, hyduronic acid, glucuronic acid, or glucosamines, pectins and/or their derivatives. 
Posebno, hidrofilni kalup predstavlja tvari odabrane, na primjer, od celuloznih derivata kao što su hidroksialkilceluloze, alkilceluloze, karboksialkilceluloze i njihove soli ili derivati, polivinilni alkoholi, karboksivinilni derivati, polisaharidni derivati anionske ili kationske prirode, kao što su npr. hiduronska kiselina, glukuronska kiselina, ili glukozamini, pektini ifili njihovi derivati.
An antibody or an antigen-binding fragment thereof according to any one of claims 1 to 12, a chimeric molecule according to claim 13, a chimeric antigen receptor according to claim 14, a polynucleotide according to claim 15 or 16, or a cell according to claim 17 for use according to claim 23 in the treatment of cancer selected in the group of breast cancer, renal cancer, bladder cancer, lung cancer, pancreatic cancer, or for the treatment of a T cell cutaneous lymphoma, such as Sezary lymphoma, or for the treatment of the acute lymphoblastoid leukemia with gain-mutation of the IL7-R/TSLP pathway and mesothelioma. 
Antitijelo ili njegov antigen-vezujući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 12, himerna molekula u skladu s patentnim zahtjevom 13, himerni receptor antigena u skladu s patentnim zahtjevom 14, polinukleotid u skladu s patentnim zahtjevom 15 ili 16, stanica u skladu s patentnim zahtjevom 17 za uporabu u skladu s patentnim zahtjevom 23 u liječenju raka izabranog iz grupe raka dojke, raka bubrega, raka mokraćnog mjehura, raka pluća, raka gušterače, ili za liječenje T-staničnog kožnog limfoma, kao što je Sezaryjev limfom, ili za liječenje akutne limfoblastične leukemije s mutacijom stjecanja funkcije 11.7-R/TSLP puta i mezotelioma.
Process and facility for the treatment of livestock waste 
PROCES I POSTROJENJE ZA OBRADU OTPADA STOKE
a contiguous sequence of the human λ light chain locus that spans from hVλ3-12 through hVλ3-1; 
(a) susjedne sekvence lokusa humanog lakog 2 lanca koja se proteže od VA3-12 do V23-1;
The composition for use according to any one of claims 1 to 6, wherein the composition is to be administered to a subject by means selected from intramuscular, intraperitoneal, intravenous, subcutaneous, rectal, nasal, oral, intragastric and pulmonary. 
Sastav za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu je sastav za davanje subjektu intramuskularno, intraperitonealno, intravenski, subkutano, rektalno, nazalno, oralno, intragastrično i plućno.
A method of controlling phytopathogenic diseases on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a combination of components A) and B) in a synergistically effective amount, wherein 
HR P20110476 T1 PATENTNI ZAHTJEVI Postupak za kontrolu fitopatogenih gljivica na korisnom bilju ili na njihovom materijalu za razmnožavanje, naznačen time, da sadrži primjenu na korisno bilje, na njihov lokus ili na njihov materijal za razmnožavanje kombinacije komponenti A) i B) u sinergistički učinkovitoj količini, pri čemu komponenta A) je spoj formule I
A mouse embryo comprising, made from, or obtainable from, the mouse ES cell of claim 8, wherein the mouse embryo comprises in its genome an endogenous λ light chain immunoglobulin locus comprising a deletion of the endogenous mouse VλI-Jλ3-Cλ3-Jλ1-Cλ1 gene cluster and a deletion of a region spanning from Vλ2 to Jλ2 of the endogenous mouse Vλ2-Vλ3-Jλ2-Cλ2-Jλ4-Cλ4 gene cluster, wherein the endogenous λ light chain immunoglobulin locus retains endogenous Cλ2, Jλ4 and Cλ4 gene segments. 
Mišji embrio koji sadrži, se sastoji od ili se može dobiti iz mišje ES stanice prema zahtjevu 8, naznačen time, što mišji embrio u svom genomu sadrži endogeni lokus imunoglobulina lakog lanca A koji se sastoji od brisanja endogenog mišjeg VM -JX43-C23-J41-C4M1 klastera gena i brisanja regije koja se proteže od VA2 do JA2 endogenog mišjeg VA2-V23-JX2-C22-JM4-C24 klastera gena, naznačen time, što endogeni lokus imunoglobulina lakog lanca A zadržava endogene C22, IMA 1 CIA genske segmente.
the agent for treatment of dyslipidaemia is a statin, a fibrate, a niacin and/or a cholesterol absorption inhibitor. 
sredstvo za liječenje dislipidemije je statin, fibrat, niacin i/ili inhibitor apsorpcije kolesterola.
The formulation of claim 1, comprising the buffer, wherein the buffer is selected from the group consisting of a carboxylic acid having from 1 to 16 carbon atoms, an alkali metal salt, an alkali earth metal salt, an ammonium salt, and a soluble metal salt. 
Formulacija lijeka s produljenim oslobađanjem za koju se traži zaštita patentom u bilo kojem od prethodnih patentnih zahtjeva, pri čemu unutarnji sloj sadrži puferski agens odabran iz anorganske soli ili farmaceutski prihvatljive karboksilne kiseline koja ima od 1 do 16 atoma ugljika.
The method of claim 7, wherein the unenriched renewable fuel oil has a solids content of less than 0.5 wt. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time što neobogaćeno obnovljivo ulje goriva ima sadržaj krutina od manje od 0,5 wt.
The process according to anyone of claims from 1 to 17, wherein the remaining part of the catalytic composition, which is not sent to the regenerator, is recycled directly to the dehydrogenation section. 
Postupak u skladu s patentnim zahtjevom 16, naznačen time što se preostali dio katalitičke smjese koji se ne šalje u regenerator reciklira izravno u dehidrogenacijski odjeljak.
to form said dihydrochloride salt of formula (II): 
[image] poželjno u suspenziji, te na taj način nastaje navedena dihidrokloridna sol s formulom (II):
Barzanò & Zanardo Milano S.p.A. A system for protecting an electric line for railway signals, 
Sirti S.p.A., Via Stamira D'Ancona 9, 20127 Milano, IT (72) izumitelji:
A cell comprising the vector of claim 15. 
Stanica, naznačena time što sadrži vektor u skladu s patentnim zahtjevom 15.
Telecommunications network (100) according to claim 9, wherein the first network node (101) and the second network node (102) are directly connected to each other. 
Telekomunikacijske mreže (100) prema zahtjevu 7, pri čemu su prvo mrežno čvorište (101), i drugo mrežno čvorište (102) izravno međusobno povezani.
calculation of the value of a function representative of the residual data items of said determined subset, 
- < izračunavanje (D5) vrijednosti funkcije koja predstavlja paritet zbroja preostalih stavki podataka navedenog određenog podskupa,
surfactant in an amount of from 5% to 30%; and glycerine in an amount of from 15% to 30%, present in an amount by weight of the total composition, wherein the bulking agent is selected from talc, kaolin, calamine, magnesium carbonate and mixtures thereof, and wherein the surfactant is selected from the group consisting of sodium laureth sulfate, sodium lauryl sulfate, cocamide diethanolamine, lauryl betaine, sodium lauroyl sarcosinate, and mixtures thereof; 
(111) surfaktant u količini od 5% do 30%; 1 (iv) glicerin u količini od 15% do 30%, prisutne u količini po masi ukupnog pripravka, pri čemu je punilo odabrano od talka, kaolina, kalamina, magnezijevog karbonata i njihovih smjesa, te pri čemu je surfaktant odabran iz skupine koju čine natrijev lauret sulfat, natrijev lauril sulfat, kokamid dietanolamin, lauril betain, natrijev lauroil sarkozinat, i njihove smjese; pri čemu čvrsti kozmetički pripravak može uglavnom održati svoj fizički oblik kada nije podržan s vanjskim sredstvima, te je kruta tvar na sobnoj temperaturi i ostaje uglavnom u čvrstom stanju pri temperaturi do 30*C.
Here, solid Na2SO4 was added to a solution of Formula 39 (24.45 g, 24.0 mmol) and 4-methyl morpholine N-oxide (10.1 g, 84 mmol) in DCM (340 mL) to assure that the reaction was dry. 
Ovdje je krutina Na»SO, bila dodana u otopinu formule 39 (24.4 g, 24.0 mmol) 1 4-tnetil morfolin N-oksida (10.1 g, 84 mmol) u DCM (340 mL) da bi se osiguralo da reakcija bude suha.
The great advantage of this solution compared to the existing ones is its robustness. An apparatus for compensating ground fault currents connected to phase conductors of a distribution system characterized by that it is a controlled current source (1) connected in-between phase conductors of the transformer (3) of the distribution system and the earth potential and is configured to compensate ground fault currents and higher harmonics of fault currents at the point of ground fault (2), further configured to compensate phase non-symmetry in trouble-free state of a distribution system, also configured to compensate higher harmonics of the distribution system and to compensate reactive power of the distribution system. 
Uređaj za kompenzaciju kvara strujnih uzemljenja spojenih na fazne konduktore u sustavu distribucije, naznačen time, da je to upravljani strujni izvor (1) spojen između faznih konduktora od transformatora (3) u sustavu distribucije i naponskog uzemljenja, koji je konstruiran za kompenzaciju kvarova strujnih uzemljenja i viših pulzacija strujnih kvarova na točki kvara uzemljenja (2), te je nadalje konstruiran za kompenzaciju fazne nesimetrije u sustavu distribucije kada je on u stanju ispravnosti, i također je konstruiran za kompenzaciju viših pulzacija u sustavu distribucije i za kompenzaciju reaktivnog kapaciteta u sustavu distribucije.
The ultrafilter was stored in 0.05M NaOH at +4°C ± 3°C until the next cycle. 
Ultrafilter je bio uskladišten u 0.05M NaOH na temperaturi od +4*C + 3%C sve do slijedećeg ciklusa.
The compounds of the general formula I may exist as optical isomers thereof and such optical isomers are also embraced by the invention. 
Spojevi općenito dani formulom I mogu doći kao optički izomeri i kao takvi optički izomeri su također obuhvaćeni ovim izumom.
Subsequently, these flakes are gently milled to obtain the required particle size density. 
Potom se pahuljice nježno samelju u čestice željene veličine.
This was stirred for 3 h at rt and concentrated. 
Ovo je miješano 3 sata na sobnoj temperaturi i koncentrirano.
a terpene oil content greater than 1.3%; and a THCV or CBDV content of greater than 4.0%; wherein the terpene oil content is the additive content of the terpenes in the terpene profile, wherein the terpene profile consists of terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool, caryophyllene oxide, and myrcene of the plant, and wherein the cannabinoid and terpene contents are measured by GC-FID and calculated based on weight of the extract, wherein extracts comprising a), b), and c) are obtainable from a plant comprising the inflorescence of any one of claims 1-10. 
Cc) - terpenski profil u kojem mircen nije dominantni terpen; i d) = sadržaj terpenskog ulja veći od 1,3%, težinski; gdje je sadržaj terpenskog ulja aditivan sadržaj terpena u terpenskom profilu, gdje se terpenski profil sastoji od terpinolena, o-felandrena, B-ocimena, karena, limonena, y-terpinena, o-pinena, a-terpinena, B-pinena, fenhola, kamfena, o-terpineola, o-humulena, B-kariofilena, linaloola, kariofilen-oksida, te mircena of the biljka, te gdje se sadržaje kanabinoida i terpena mjeri uz pomoć GC-FID, te izračunava na osnovi težine ekstrakta, gdje se ekstrakte koji sadrže a), b), c), te d) može dobiti iz biljke koja sadrži inflorescenciju u skladu s patentnim zahtjevom 1.
A pharmaceutical composition according to enbodiments33 or 34, further comprising one or more additional active agents. 
Farmaceutski sastav prema zahtjevu 18 ili 19, naznačen time, da nadalje obuhvaća jedno ili više dodatnih djelotvornih sredstava.
A slab as claimed in claim 19, characterised by presenting three layers. 
Ploča kao što je navedena u patentnom zahtjevu 19, naznačena time što ima tri sloja.
The method of claim 1, wherein the outer (N-terminal) variable light chain domain comprises an amino acid sequence that has 95% identity to the amino acid sequence of SEQ ID NO: 1, the inner (C-terminal) variable light chain domain comprises an amino acid sequence that has 95% identity to the amino acid sequence of SEQ ID NO: 3, the outer (N-terminal) variable heavy chain domain comprises an amino acid sequence that has 95% identity to the amino acid sequence of SEQ ID NO: 2, and the inner (C-terminal) variable heavy chain domain comprises an amino acid sequence that has 95% identity to the amino acid sequence of SEQ ID NO: 5. 
Bispecifično antitijelo ili njegov bispecifični fragment antitijela koji se specifično veže na IL-13 1 IL-4, naznačeno time da navedeno bispecifično antitijelo ili njegov bispecifični fragment antitijela sadrži dva laka lanca sa strukturom N-VLyB-Bi3-poveznica-VLyppp4.g-CL-C i dva teška lanca sa strukturom N-VHlip.Bi3-poveznica-V Hypp4-g-CH1-CH2-CH3-C, pri čemu VLip-pi3 sadrži sekvencu aminokiseline SEQ ID NO: 1, pri čemu VLyppa.g sadrži sekvencu aminokiseline SEQ ID NO: 3, pri čemu VHip.pi3 sadrži sekvencu aminokiseline SEQ ID NO: 2, pri čemu VHhipna-s sadrži sekvencu aminokiseline SEQ ID NO: 4, te pri čemu svaka poveznica je peptidna poveznica koja ima sekvencu aminokiseline koja sadrži SEQ ID NO: 6.
filling the ingredient mix into packaging, and heating the ingredient mix in the packaging to a temperature in the range of at least 90°C, maintaining the ingredient mix at the temperature selected in g) for a period of time selected from the range from 30 seconds to 9 hours, thereby forming a sliceable dairy food product. 
€) homogeniziranje mješavine sastojaka; 1) punjenje ambalaže mješavinom sastojaka, 1 2) zagrijavanje mješavine sastojaka u ambalaži, na temperaturu u rasponu od 90*C do 155*C, h) držanje mješavine sastojaka na temperaturi odabranoj u g) tijekom vremenskog perioda u rasponu od 30 sekundi do 9 sati, čime se oblikuje mliječni prehrambeni proizvod koji se može rezati.